Triple Therapy for Diabetic Macular Edema: Intravitreal Bevacizumab, Triamcinolone Acetonide and Macular Photocoagulation

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-09000606

Enrollment

Unknown

Registered

2009-12-05

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema

Interventions

Group A :Bevacizumab

Eligibility

Sex/Gender

Male

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Eyes with diabetic macular edema; 2. BCVA between 20/40 and >= 20/800 and CMT measured by OCT greater than 250 microns.

Exclusion criteria

Exclusion criteria: Proliferative diabetic retinopathy and hard exsudates in the fovea.

Design outcomes

Primary

Measure	Time frame
Changes in best-corrected visual acuit;	—

Countries

Brazil

Contacts

Public ContactArnlado F Bordon

afbordon@terra.com.br+55 1532127000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026